ACRO Biomedical was established in June 2014. In August of the same year, Ministry of Science and Technology of Taiwan granted ACRO Biomedical the use of a standard manufacturing facility in Southern Taiwan Medical Device Industry Cluster. In collaboration with Animal Technology Laboratories (ATL) of Agricultural Technology Research Institute (ATRI), ACRO Biomedical aims to develop medical-grade regenerative biomaterials.
To this end, ACRO Biomedical draws on the best and the brightest of major science and technology research institutes and biomedical research centers in Taiwan. Its shareholders include major corporate partners, seasoned biotechnology and chemical engineering companies of Taiwan, professors of major teaching and research institutes, and renowned medical doctors. The biomaterials in development will be used for tissue repairs in areas such as orthopedics, dentistry, cardiovascular grafts, ophthalmology, surgeries, wound repairs, sports injuries, and etc.
Awarded the 21st National Innovation Award approval for Innovative application of acellular dermal matrix (micro-particle) in medical devices..
Received U.S. FDA 510(k)approval for ABCcolla® Collagen ADM Scaffold..
Received EU patent -Preparation of high purity collagen particles and uses thereof.
Received TFDA Class III Medical Device approval for Hemostatic Collagen Matrix.
Received TFDA Class III Medical Device approval for Hemostatic ADM Scaffold.
Received TFDA Class III Medical Device approval for Hemostatic ADM Paste.
Received USA patent - Acellular organs, and methods of producing the same.
Received China patent - Acellular organs, and methods of producing the same.
Received The Pharmaceutical Technology & Research Development Award 2023 - Silver Award in Manufacturing Technology
Received Singapore patent - Acellular organs, and methods of producing the same.
Awarded Symbol of National Quality for Acellular Dermal Patch.
Obtained export license for Corneal Matrix.
Received 2023 Taiwan BIO Awards - Innovation of the Year - The application of scCO2 platform technology in regenerative medicine industry
Received TFDA Class II Medical Device approval for Acellular Dermal Patch.
Received TFDA Class II Medical Device approval for Type II Collagen Powder.
Received Korea patent - Acellular organs, and methods of producing the same.
Received Taiwan patent - Use of collagen particles in hair follicles formation or angiogenesis.
Received TFDA Class II Medical Device approval for ADM Collagen Paste.
Received EU patent - Acellular organs, and methods of producing the same.
Received import license for Collagen Matrix in India.
Received The National Innovation Award third-time renewal for Collagen Ophthalmic Matrix.
Received The National Innovation Award renewal for ACRO Biomedical Tissue and Organ Regenerative Technology
Received Taiwan Biopharma Excellence Awards 2022 in Best Platform Technology Award.
Received Japan patent - Acellular organs, and methods of producing the same.
Awarded the 2022 Taipei Biotech Awards Innovation Bronze Medal Award.
Received approval for Collagen Membrane from Philippine FDA.
Received approval for Collagen Dental Bone Graft from Philippine FDA.
Received TFDA Class II Medical Device approval for Collagen ADM Scaffold.
Received TFDA Class II Medical Device approval for EZ Collagen Bone Graft.
Received Hong Kong patent - Preparation of high purity collagen particles and uses thereof.
Received China patent - Preparation of high purity collagen particles and uses thereof.
Awarded Symbol of National Quality for Collagen Bone Matrix.
Received The National Innovation Award second-time renewal for Collagen Ophthalmic Matrix.
Awarded the 18th National Innovation Award for ACRO Biomedical Tissue and Organ Regeneration Technology.
Received US patent - Preparation of acellular cartilage graft and uses thereof.
Received U.S. FDA 510(k) for Collagen Bone Matrix.
Received Hong Kong patent - Acellular corneas, methods of producing the same and uses thereof.
Received Hong Kong patent - Preparation of acellular cartilage graft and uses thereof.
Received The 18th National Brand Yushan Award for Most Outstanding Enterprise.
Registered on Emerging Stock Market
Received EU patent - Preparation of acellular cartilage graft and uses thereof.
Received Japan patent - Preparation of high purity collagen particles and uses thereof.
Received India patent - Acellular corneas, methods of producing the same and uses thereof.
Received China patent - Acellular corneas, methods of producing the same and uses thereof.
Received China patent - Preparation of acellular cartilage graft and uses thereof.
Received India patent - Preparation of acellular cartilage graft and uses thereof.
Received Hong Kong patent - Apparatus for treating animal skin tissue and a method for using the same.
Received US patent - Preparation of high purity collagen particles and uses thereof.
Received Taiwan patent - Acellular organs, and methods of producing the same.
Received EU patent - Acellular corneas, methods of producing the same and uses thereof.
Received India patent - Preparation of hight purity collagen particles and used thereof.
Received TFDA Class II Medical Device approval for Collagen Bone Matrix.
Received Korea patent - Preparation of high purity collagen particles and uses thereof.
Received Taiwan patent - Acellular bone graft and artificial implant assembly comprising the same.
Received China patent - Apparatus for treating animal skin tissue and a method for using the same
Received Korea patent - Preparation of acellular cartilage graft and uses thereof.
Received USA patent - Acellular corneas, methods of producing the same and uses thereof.
Received Korea patent - Acellular corneas, methods of producing the same and uses thereof.
Received The National Innovation Award renewal for Collagen Ophthalmic Matrix.
Received Japan patent - Acellular corneas, methods of producing the same and uses thereof.
Received 2nd Prize in Hangzhou 2019 Innovation & Entrepreneurship Competition for Overseas Talents.
Received approval for Collagen Bone Graft from Philippine FDA.
Received Taiwan patent - Auxiliary slicing device for slicing biological tissue, kits comprising the same and uses thereof.
Received Taiwan patent - Acellular corneas, methods of producing the same and uses thereof.
Received Japan patent - Preparation of acellular cartilage graft and uses thereof.
IPO in Taipei Exchange Stock Market.
Received approval for Collagen Bone Graft from Vietnam FDA.
Received China patent - Auxiliary slicing device for slicing biological tissue, kits comprising the same and uses thereof.
Collagen Bone Graft was selected to join NASA's study on spaceflight osteopenia.
Received approval for Collagen Matrix from Philippine FDA.
Received approval for Collagen Bone Graft from Singapore FDA.
Signed MOU with Tri-Service General Hospital for joint research projects, and joined the Innovation Incubation Center.
Received approval for Collagen Matrix from Singapore FDA.
Awarded Symbol of National Quality for Collagen Bone Graft and Collagen Dental Bone Graft.
Received Taiwan patent - Preparation of acellular cartilage graft and uses thereof.
Revised ISO13485: 2016 - International Management System Certificate.
Received ASPA Award for Excellence Prize, in recognition of the contribution towards the development of Asian industry and technology.
Received approval for Collagen Matrix from Vietnam FDA.
Received TFDA approval for conducting human clinical trial for ABCcolla® Collagen Ophthalmic Matrix.
Received TFDA Class II Medical Device approval for Collagen Membrane.
Received Taiwan Golden Root Award from Vice President of Taiwan.
Received U.S. FDA 510(k) for Collagen Bone Graft.
Received TFDA Class II Medical Device approval for Collagen Dental Bone Graft.
Received National Innovation Award for Collagen Ophthalmic Matrix product.
Awarded Symbol of National Quality for Collagen Matrix and Collagen Revitalizing Serum.
Licensed out Collagen Ophthalmic Matrix to Oculus BioMed for Australian/New Zealand market.
Received TFDA Class II Medical Device approval for Collagen Bone Graft.
Signed exclusive distributorship with Marubeni for all product lines in the Japan.
Received Taiwan patent-Preparation of high purity collagen particles and uses thereof.
Received Taiwan patent-Apparatus for treating animal skin tissue and a method for using the same.
Received U.S. FDA 510(k) and TFDA Class II Medical Device approval for Collagen Matrix.
Approved by the Ministry of Economic Affairs as an Emerging Biotech Company.
Interviewed and broadcasted by Discovery Channel for the world's first successful canine corneal transplantation.
Conducted world's first successful canine corneal transplantation.
Launched ACRODERM skin care series products.
Received approval for 4 Class I Medical Devices from Taiwan FDA.
Submitted Collagen Matrix to U.S. FDA for medical device product registration.
Received GMP management system approval for medical device from Taiwan FDA.
Received ISO13485 – Medical Device Quality Management System Certification.
Acquired license for Manufacture and Sale of Therapeutic Medical Device Products.
Constructed GMP factory in Kaohsiung Science Park.
Company established by a group of scientists, professors, doctors and angel investors.